Antihypertensive Class Labeling On Trial Outcomes Data To Be Assessed
Executive Summary
FDA's Cardiovascular & Renal Drugs Advisory Committee will address the generalizability of clinical outcome trials for antihypertensive drug products at its June 15 meeting